Novo Nordisk
Novo Nordisk is a Series A to growth stage investment firm. It has made 6 investments. Average disclosed round size is $106.1M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Amalgam Rx | Series A | $20M | Jan 2023 |
 Inversago Pharma | Series C | — | Jan 2023 |
| Inversago Pharma | Growth | $110M | Jan 2023 |
 Beta Bionics | Series C | $57M | Feb 2022 |
 BIOMILQ | Series A | $3.5M | Oct 2021 |
 Xencor | Unknown | $45M | — |
| EElevateBio, LLC | Series D | $401M | — |
Top Co-Investors
New Enterprise Associates2 shared
Forbion2 shared
Catalio Capital Management1 shared
CVS Health1 shared
Pura Vida Investments1 shared
RTW Investments, LP1 shared
Scale Venture Partners1 shared
Eventide Asset Management1 shared
Farallon Capital Management1 shared
LifeSci Venture Partners1 shared
Perceptive Advisors1 shared
ArrowMark Partners1 shared
Soleus Capital1 shared
Novo Holdings A/S1 shared
Pivotal Life Sciences1 shared
EDBI1 shared
ITOCHU Corporation1 shared
Fidelity Investments1 shared
MPM Capital1 shared
Last updated: 19 September 2026